Vasculitis & polymyalgia rheumatica
Assessment of Giant Cell Arteritis–Associated Visual Outcomes at a Tertiary Hospital in Ontario, Canada
Main finding · Visual improvement after treatment (GCAVCs)Result — go to the resultAdjusted odds ratio 0.43-1.72 95% CI 0.02–123.68Authors' conclusion
GCAVCs are common and frequently associated with permanent vision loss. Although the precision of our results was limited by sample size, we did not find evidence that receiving IV GCs before oral GCs was associated with visual improvement in GCAVCs.
Study context
- Population
- Individuals aged ≥ 50 years with giant cell arteritis (GCA) (ICD-10 code, verified, supported by histologic, radiographic and/or biochemical evidence) and a healthcare visit Nov 2017–Dec 2023, tertiary facility in Ontario, Canada77 with GCAVCs
- Participants
- 289 individuals
- Exposure
- Intravenous (IV) vs oral glucocorticoids (GCs) as first GC exposure in GCA-associated vision changes
- Outcome
- Reported visual improvement after treatment
Methodological detailssingle-centre (tertiary healthcare facility), logistic regression adjusted for demographic and disease factors
- Single-centre (tertiary healthcare facility)
- Logistic regression adjusted for demographic and disease factors
Main finding
Visual improvement after treatment (GCAVCs)
Adjusted odds ratio
0.43-1.72
95% CI 0.02–123.68
As reported in the abstract
Observational data: associations, not effects.
Further findings
Prevalence of GCAVCs among patients with GCA
- Patients with GCAVCs
- 77 (26.6%)
Outcomes of GCAVCs
- GCAVCs leading to permanent vision loss
- 70.1%
- Visual recovery
- 16%
Original publication
Assessment of Giant Cell Arteritis–Associated Visual Outcomes at a Tertiary Hospital in Ontario, Canada. J Rheumatol. Published 1 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →